Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 21.36
- Piotroski Score 1.00
- Grade Outperform
- Symbol (CATX)
- Company Perspective Therapeutics, Inc.
- Price $6.97
- Changes Percentage (-11.63%)
- Change -$0.92
- Day Low $6.79
- Day High $7.95
- Year High $19.10
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $21.00
- High Stock Price Target $24.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.17
- Trailing P/E Ratio -7.06
- Forward P/E Ratio -7.06
- P/E Growth -7.06
- Net Income $-14,670,000
Income Statement
Quarterly
Annual
Latest News of CATX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?
A list of the top 10 Multibagger Stocks for 2025 includes Perspective Therapeutics, Inc. Amid market events, Fed Chair Powell indicated no immediate rate cuts due to solid economic growth and inflatio...
By Yahoo! Finance | 2 days ago
